Navigation Links
Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award

COVINGTON, Ky., April 18, 2011 /PRNewswire/ -- Bexion Pharmaceuticals was named the Biotech Innovation Award winner at the Cincinnati USA Innovation Awards program sponsored by the Cincinnati Business Courier, the Cincinnati USA Regional Chamber and CincyTech.  The Innovation Awards celebrate outstanding innovation and the companies and people who have shown how new ideas can be developed into fuel for the regional Tri-State (Ohio/Kentucky/Indiana) economic engine.

"The Bexion team is honored to be the very first winner of the Biotech Innovation Award," stated Dr. Ray Takigiku, co-founder and CEO of Bexion.  "Cancer treatment and diagnosis is in dire need of innovation.  We believe, and the award judges appear to agree, that our approach represents an entirely new, exciting and potentially paradigm-shifting approach to the treatment of cancer."

Bexion is developing BXQ-350 nanovesicles as a potential treatment for the form of brain cancer called glioblastoma.  BXQ-350 nanovesicles have an affinity for the membrane patches that are common in many types of tumor cells including glioblastoma cells. Bexion's studies have shown effectiveness in the laboratory in multiple animal tumor models, and across a remarkable range of tumors in the test tube.

About Bexion Pharmaceuticals:Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer.  Initial products are based on a patent-protected and proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center.  The technology has demonstrated potential for development as therapeutics, diagnostics and surgical imaging reagents, as well as carriers for other pharmaceutical agents, such as oligonucleotides.  For more information, visit media enquiries contact:

For investor enquiries contact:Margaret van GilseChuck ScheperVP, Business Development

ChairBexion Pharmaceuticals, LLC

Bexion Pharmaceuticals, LLC632 Russell Street

632 Russell StreetCovington, KY 41011

Covington, KY 41011Phone: (513) 833-7065

Phone: (513)

SOURCE Bexion Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
2. Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
3. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
4. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
5. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
6. Amylin Pharmaceuticals Reports First Quarter Financial Results
7. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
8. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
9. Endo Pharmaceuticals to Announce First Quarter 2011 Financial Results on April 28, 2011
10. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
11. Novis Pharmaceuticals Celebrates Four Years With New Website Launch
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):